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Array analysis of cycloxygenase-deficient mice <p>Microarray analysis of gene expression in the cerebral cortex and hippocampus of mice deficient in cyclooxygenase-1 or cyclooxygen- ase-2 reveals that the two enzymes differentially modulate brain gene expression.</p>
Abstract
Background: Cyclooxygenase (COX)-1 and COX-2 produce prostanoids from arachidonic acid
and are thought to have important yet distinct roles in normal brain function. Deletion of COX-1
or COX-2 results in profound differences both in brain levels of prostaglandin E2 and in activation
of the transcription factor nuclear factor-κB, suggesting that COX-1 and COX-2 play distinct roles
in brain arachidonic acid metabolism and regulation of gene expression. To further elucidate the
role of COX isoforms in the regulation of the brain transcriptome, microarray analysis of gene
expression in the cerebral cortex and hippocampus of mice deficient in COX-1 (COX-1-/-) or
COX-2 (COX-2-/-) was performed.
Results:  A majority (>93%) of the differentially expressed genes in both the cortex and
hippocampus were altered in one COX isoform knockout mouse but not the other. The major
gene function affected in all genotype comparisons was 'transcriptional regulation'. Distinct biologic
and metabolic pathways that were altered in COX-/- mice included β oxidation, methionine
metabolism, janus kinase signaling, and GABAergic neurotransmission.
Conclusion: Our findings suggest that COX-1 and COX-2 differentially modulate brain gene
expression. Because certain anti-inflammatory and analgesic treatments are based on inhibition of
COX activity, the specific alterations observed in this study further our understanding of the
relationship of COX-1 and COX-2 with signaling pathways in brain and of the therapeutic and
toxicologic consequences of COX inhibition.
Background
Prostaglandin H synthase, otherwise known as cyclooxygen-
ase (COX), catalyzes the first metabolic step in the transfor-
mation of arachidonic acid (AA) to the bioactive products
prostaglandins and thromboxanes [1]. The existence of two
isoforms of prostaglandin H synthase, namely COX-1 and
COX-2, has been confirmed in multiple organs, including
brain [2,3]. Not only are these enzymes physiologically
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important in their role in AA metabolism but they are also
important pharmacologic targets of analgesics and anti-
inflammatory agents [3]. Mice deficient in either COX-1
(COX-1-/-) or COX-2 (COX-2-/-) are available and have been
used to advance our understanding of the physiologic and
pathologic roles of the individual COX isoforms [4].
Although it is known that in brain both COX-1 and COX-2 are
expressed constitutively and that COX-2 can be induced upon
the presence of an insult, complete understanding of the role
of each individual isoform is lacking. Our laboratory has
attempted to elucidate the role of each isoform on brain phys-
iology by using COX-1-/- and COX-2-/- mice. We found that
COX-2-/-  mice have altered expression and activity of
enzymes in the AA metabolism cascade, including increases
in COX-1, cytosolic phospholipase A2 (cPLA2) and secretory
phospholipase A2  expression [5]. Similar alterations have
been observed in COX-1-/- mice, in which COX-2 protein
expression and cPLA2 and secretory phospholipase A2 gene
and protein expression are increased [6]. However, the levels
of prostaglandin E2, which is one of the major end products of
the COX reaction, were increased in COX-1-/-  mice but
decreased in COX-2-/- mice. In addition, it has also been
shown that COX-1-/- and COX-2-/- mice exhibit profound dif-
ferences in activation of the transcription factor nuclear fac-
tor-κB (NF-κB) [6,7]. Overall, these previous studies suggest
that each isoform and their end products, which function
through specific prostaglandin receptors, play a unique role
in the regulation of gene expression in the brain.
It has also been shown that mice with genetic deletion of an
individual COX isoform have altered responses to pathologic
insults. For instance, COX-2-/- mice are known to be more
resistant to direct cortical injections of N-methyl-D-aspar-
tate, middle cerebral artery occlusion (MCAO), and systemic
injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) [8,9]. However, the precise downstream molecular
mechanisms involved in these processes are not clearly char-
acterized. Therefore, it is quite clear that an understanding of
the COX-1-/- and COX-2-/- mouse brain transcriptome is nec-
essary to elucidate further the individual roles of COX-1 and
COX-2 in both normal brain function and response to injury.
Although previously characterized alterations in gene and
protein expression in COX-deficient mice have been exam-
ined, they were discovered in a 'one protein and one gene at a
time fashion' using Western blotting and real-time polymer-
ase chain reaction (PCR) [5-7]. The usage of high-throughput
technology such as microarray analysis can enhance our abil-
ity to characterize the effect of deleting the expression of
either COX-1 or COX-2 on the expression of networks of
genes normally controlled by the end products of these indi-
vidual COX isoforms. Therefore, we used microarray analysis
with quantitative, real-time PCR (Q-PCR) validation to deter-
mine the effect of deletion of either COX-1 or COX-2 on the
transcriptome of two separate regions of mouse brain,
namely hippocampus and cerebral cortex. Further analysis of
the entire dataset with Ingenuity Pathways analysis software
(Ingenuity Systems, Redwood City, CA, USA), a web-based
software application that assists in the analysis and elucida-
tion of complex biologic systems, revealed specific networks
of genes that were differentially regulated. We decided to
focus on gene expression changes that comprised specific bio-
logic functions, and not just individual genes that are affected
by genetic deletion of individual COX isoforms. Our findings
suggest that genetic ablation of COX activity alters the tran-
scription of a multitude of genes. Furthermore, we demon-
strate that genetic deletion of COX isoforms alters the
expression of tandem genes that are involved in metabolic
and signaling pathways such as β oxidation, methionine
metabolism,  γ-aminobutyric acid (GABA) neurotransmis-
sion, and cytokine signaling. We also describe genes differen-
tially expressed in COX-1-/- versus COX-2-/- mice, suggesting
a unique role for COX-1 or COX-2 in modulating gene
expression.
Results
Differential gene expression in COX-1-/- and COX-2-/- 
mice
In the cerebral cortex, 94 genes were differentially expressed
in COX-1-/- mice and 157 in COX-2-/- mice compared with
respective wild-type mice. In the hippocampus, 182 genes
were differentially expressed in COX-1-/- mice and 168 in
COX-2-/- mice compared with wild-type mice. These genes
represent the entire set of differentially expressed genes,
including expressed sequence tags, and RIKEN and chromo-
somal segment sequences. Further description of this dataset
includes only the subset of genes that were annotated with an
ascribed function or gene name. A complete list of the anno-
tated, differentially expressed genes for both brain regions
and all genotype comparisons can be found in the Additional
data files, and the entire raw dataset can be found in the Gene
Expression Omnibus (GEO: GSE5342).
Using DRAGON (Database Referencing of Array Genes
Online), SwissProt function labels were ascribed to each gene
and genes were parsed into categories according to the func-
tion labels. In both COX-1-/- and COX-2-/- mice, the greatest
number of genes whose expression was significantly changed
in both brain regions belonged to the SwissProt function cat-
egory of transcriptional regulation (cerebral cortex: COX-1-/-
= 12% and COX-2-/- = 7%; hippocampus: COX-1-/- = 11% and
COX-2-/- = 12%). COX-2-/- mice exhibited significant changes
in expression of genes belonging to the transmembrane (6%)
and mitochondrion (5%) functional categories in cerebral
cortex, whereas COX-1-/- mice exhibited significant alteration
in expression of genes classified as nuclear proteins (9%). In
contrast, expression of genes belonging to the kinases (7%)
functional group was selectively changed in the hippocampus
of COX-1-/- but not of COX-2-/- mice.http://genomebiology.com/2007/8/1/R14 Genome Biology 2007,     Volume 8, Issue 1, Article R14       Toscano et al. R14.3
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Although a majority of the genes (>93%) shown to be differ-
entially expressed in the separate brain regions of COX-1-/- or
COX-2-/- mice only occurred in mice null for one isoform and
not the other, the expression of some genes was changed in
both COX-1-/- and COX-2-/- mice. Table 1 lists all of the genes
whose expression was changed in both COX-1-/- and COX-2-/
- mice, either in the same or in the opposite direction. In the
cerebral cortex, there were four genes with altered expression
in both COX-1-/- and COX-2-/- mice. Of these four, Rho-GDP
dissociation inhibitor α exhibited increased expression in
both genotypes. The expression of the other three genes
(mitochondrial inner membrane protein, GABA transporter
[GAT]3, and ring finger protein 24) changed in opposite
directions (downregulated in COX-1-/- and upregulated in
COX-2-/-  mice), suggesting an isoform-specific effect on
expression of these genes. Such an isoform-specific effect was
not observed in the hippocampus, where all 12 genes whose
expression was altered in both COX-1-/- and COX-2-/- mice
exhibited changes in a similar direction in both genotypes
when compared with wild-type mice (Table 1), suggesting
that this cohort of genes is responsive to a general alteration
in AA metabolism that is not specific to COX-1 or COX-2.
Upregulation of gene expression of cPLA2, which releases AA
from phospholipids, as previously described by Q-PCR in
whole brain of COX-1-/- and COX-2-/- mice [5,6], was not
detected in cortex (COX-1: z ratio = 0.72, P = 0.03; COX-2: z
ratio = 0.04, P = 0.9) and hippocampus (COX-1: z ratio = -
0.89, P = 0.002; COX-2: z ratio = 0.60, P = 0.13) by microar-
ray analysis. Although a thorough study regarding the expres-
sion of cPLA2  mRNA in mouse brain has not been
undertaken, expression patterns of cPLA2 mRNA in rat brain
suggest elevated expression in the midbrain, thalamus,
hypothalamus, pons, and pineal gland compared with cere-
bral cortex and hippocampus [10]. Therefore, this heteroge-
neous expression of cPLA may account for the detection of
differential regulation in whole brain but not in distinct
regions, such as hippocampus and cortex.
Using Ingenuity Pathways analysis software, we identified
specific networks of genes that were differentially regulated.
These networks of genes constituted specific metabolic and
signaling pathways, including β oxidation of lipids (Figure 1),
methionine metabolism (Figure 2), GABAergic neurotrans-
mitter signaling (Table 2), and a COX isoform specific effect
on Janus kinase (JAK) expression (Table 2).
Expression of genes involved in beta oxidation is 
upregulated in cortex of COX-2-/- mice
In cerebral cortex of COX-2-/- mice, we identified increased
expression of three genes that work in tandem in the final
steps of short chain lipid metabolism by β oxidation, namely
hydroxyacyl-coenzyme A dehydrogenase type II (HADH2),
acetyl-coenzyme A acetyltransferase 1 (ACAT1) and ATP cit-
rate lyase (ACLY; Figure 1). Expression of HADH2 was deter-
mined to be increased in microarray analysis of cerebral
Table 1
Genes whose expression is altered in both COX-1-/- and COX-2-/- mice
Genbank accession number Gene name COX-1-/- versus wild 
type
COX-2-/- versus wild 
type
Cortex
BG086892 Rho GDP dissociation inhibitor (GDI) α 2.40 1.69
AW555640 Inner membrane protein, mitochondrial -5.49 2.16
BG075861 Solute carrier fam. 6 (neurotransmitter transporter, GABA), mem. 13 -1.86 1.68
BG085367 Ring finger protein 24 -2.84 2.15
Hippocampus
BG064367 Ectonucleoside triphosphate diphosphohydrolase 1 -1.84 -1.94
BG064631 Timeless homolog (Drosophila) 1.95 1.81
BG065181 RNA binding motif, single stranded interacting protein 1 1.52 2.09
BG065688 Ubiquitin A-52 residue ribosomal protein fusion product 1 3.21 2.62
BG066667 Microtubule-associated protein 4 1.6 2.07
BG067592 Nuclear receptor corepressor 2 2.13 1.54
BG067766 Nuclear receptor subfamily 1, group H, member 2 1.65 1.51
BG069493 Rho-guanine nucleotide exchange factor -1.84 -1.52
BG078482 Synaptotagmin binding, cytoplasmic RNA interacting protein 1.67 1.84
BG079093 Glycolipid transfer protein 2.26 2.02
BG081977 THAP domain containing 11 -1.85 -1.94
BG083840 Mitogen-activated protein kinase 13 2.06 2.23
Gene names are provided with GenBank accession numbers and z ratio. A positive z-ratio represents an increase in expression in COX-/- mice while 
a negative value denotes a decrease in expression in COX-/- mice. COX, cyclooxygenase.R14.4 Genome Biology 2007,     Volume 8, Issue 1, Article R14       Toscano et al. http://genomebiology.com/2007/8/1/R14
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cortex of COX-2-/- mice with a z ratio of +1.60. Q-PCR also
demonstrated an increase in HADH2 expression (143% ±
24% in COX-2-/- mice versus 100% ± 20% in wild-type mice;
t  statistic = -3.26, P  = 0.01). ACAT1 expression was also
increased in cerebral cortex of COX-2-/- mice (z ratio = +1.83),
β Oxidation gene expression is increased in cerebral cortex of cyclo-oxygenase (COX)-2-/- mice Figure 1
β Oxidation gene expression is increased in cerebral cortex of cyclo-oxygenase (COX)-2-/- mice. The expression of three tandem genes involved in the 
metabolism of short chain fatty acids to citrate is increased in cerebral cortex of COX-2-/- mice, as determined by microarray and quantitative PCR (Q-
PCR) analysis. These genes, namely hydroxyacyl coenzyme-A dehydrogenase (HADH2), acetyl coenzyme-A acetyltransferase (ACAT1) and ATP citrate 
lyase, are depicted in the ovals above, along with the enzyme classification (EC) number in parenthesis. Z ratio from the microarray analysis and Q-PCR 
validation results for each gene are provided below the name of the gene. A positive z ratio represents an increase in expression in COX knockout mice, 
whereas a negative value denotes a decrease in expression in COX knockout mice. Q-PCR percentage represents the percentage increase in expression 
over wild-type mice. HADH2 and ACAT1 are expressed in the mitochondria and ATP citrate lyase is expressed in the cytosol. The expression of genes 
represented as a square is not changed.
Fatty Acid
3-hydroxyacyl
CoA
HADH2 (1.1.1.35)
Z-score= +1.60
Q-PCR= +43%
3-ketoacyl
CoA CoA
ACAT1 (2.3.1.9)
Z-score= +1.83
Q-PCR= +58%
Acetyl CoA
Acetyl CoA
Citrate
synthase
Citrate
MITOCHONDRIA
Citrate
ATP
CoA
ATP Citrate Lyase (2.3.3.8)
Z-score= +1.65
Q-PCR= +88%
Acetyl CoA
CYTOSOL
Methionine metabolism gene expression is increased in the cerebral cortex of cyclo-oxygenase (COX)-2-/- mice Figure 2
Methionine metabolism gene expression is increased in the cerebral cortex of cyclo-oxygenase (COX)-2-/- mice. The expression of two tandem genes 
involved in the metabolism of methionine to homocysteine is increased in the cortex of COX-2-/- mice, as determined by microarray and quantitative PCR 
(Q-PCR) analysis. These genes, namely methionine adenosyltransferase (MAT2B) and S-adenosylhomocysteine hydrolase (AHCY), are depicted in the 
ovals above, along with the enzyme classification (EC) number in parenthesis. Z ratio from the microarray analysis and Q-PCR validation results for each 
gene are provided below the name of the gene. A positive z ratio represents an increase in expression in COX knockout mice, whereas a negative value 
denotes a decrease in expression in COX knockout mice. Q-PCR percentage represents the percentage increase in expression over wild-type mice.
L-methionine
MAT2B (2.5.1.6)
Z-score= +2.79
Q-PCR= +38%
Methyltransferases S-adenosyl-
L-methionine
S-adenosyl-
L-homocysteine
AHCY (3.3.1.1)
Z-score= +1.66 
Q-PCR= +23%
L- homocysteinehttp://genomebiology.com/2007/8/1/R14 Genome Biology 2007,     Volume 8, Issue 1, Article R14       Toscano et al. R14.5
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which was validated by Q-PCR analysis (158% ± 19% in COX-
2-/- mice versus 100% ± 10% in wild-type mice; t statistic = -
6.13, P = 0.0003). Finally, ACLY expression was increased in
microarray analysis of the cerebral cortex of COX-2-/- mice (z
ratio = +1.65), and the increase was also validated with Q-
PCR (188% ± 33% in COX-2-/- mice versus 100% ± 49% in
wild-type mice; t statistic = -3.41, P = 0.008). Gene expres-
sion of ACAT 1, but not that of HADH2 and ACLY, was found
to be decreased in the hippocampus of COX-1-/- mice (z ratio=
-3.00; 72% ± 6% in COX-1-/- mice versus 100% ± 21% in wild-
type mice; t statistic = 2.99, P = 0.03).
Expression of genes involved in methionine 
metabolism is upregulated in cortex of COX-2-/- mice
Expression of methionine adenosyltransferase II (MAT2B)
and adenosylhomocysteine hydrolase (AHCY), two genes that
work in tandem to metabolize methionine to homocysteine,
was increased in cerebral cortex of COX-2-/- mice (Figure 2).
MAT2B expression was found to be increased in microarray
analysis (z ratio = +2.79) and by Q-PCR analysis (138% ± 12%
in COX-2-/- mice versus 100% ± 25% in wild-type mice; t sta-
tistic = -3.14, P  = 0.013). Increased AHCY expression, as
detected by microarray analysis (z ratio= +1.66), was vali-
dated by Q-PCR (123% ± 5% in COX-2-/- mice versus 100% ±
14% in wild-type mice; t statistic = -3.76, P = 0.01). Expres-
sion of MAT2B, but not of AHCY, was decreased in COX-1-/-
hippocampus (z ratio = -3.07; 78% ± 13% in COX-1-/- mice
versus 100% ± 18% in wild-type mice; t statistic = 2.39, P =
0.04).
GABA transporter and receptor expression is altered 
in COX-/- mice
Expressions of two genes that are involved in GABA neuro-
transmission were altered in cerebral cortex and
hippocampus of COX knockout mice. Microarray analysis of
GABA-A receptor subunit β1 (GABRB1) in the hippocampus of
COX-2-/- mice demonstrated downregulation (z ratio = -2.32)
of gene expression (Table 2). Validation with Q-PCR demon-
strated that the expression of GABRB1 was not only decreased
in hippocampus of COX-2-/- mice (54% ± 18% in COX-2-/-
mice versus 100% ± 19% in wild-type mice; t statistic = 4.08,
P = 0.003) but it was also decreased in cerebral cortex of
COX-2-/- mice, a change that was not initially detected by
microarray analysis (72% ± 8% in COX-2-/- mice versus 100%
± 17% in wild-type mice; t statistic = 3.67, P = 0.008).
GABA transporter (GAT)3 expression in cerebral cortex of
COX-/- mice exhibited a genotype-specific effect (Table 2).
COX-1-/- mice demonstrated downregulation of gene expres-
sion (z ratio = -1.86) whereas COX-2-/- showed upregulation
of mRNA level (z ratio = +1.68). Validation with Q-PCR dem-
onstrated the same pattern of expression in COX-1-/- mice
(58% ± 12% in COX-1-/- mice versus 100% ± 22% in wild-type
mice; t statistic = 3.70, P = 0.006) and COX-2-/- mice (166% ±
37% in COX-2-/- mice versus 100% ± 13% in wild-type mice; t
statistic = -3.82, P = 0.01). No significant difference in the
expression of GAT3 was detected by microarray or Q-PCR in
the hippocampus of any mice examined in the present study
(data not shown).
Janus kinase expression is altered in a genotype-
dependent manner in hippocampus
Janus kinase (JAK) isoforms 1 and 2 were found to be
expressed in a genotype-dependent manner in hippocampus
(Table 2). COX-1-/- mice had increased expression of JAK1 (z
ratio = +1.56) but not of JAK2. Q-PCR validation also demon-
strated increased expression of JAK1 in COX-1-/- mice (196%
± 79% in COX-1-/- mice versus 100% ± 40% in wild-type mice;
t  statistic = -2.45, P  = 0.04). On the other hand, JAK-2
expression was decreased in COX-2-/- but not in COX-1-/- mice
(z ratio = -2.09). Validation with Q-PCR confirmed this selec-
tive decrease (82% ± 12% in COX-2 -/- mice versus 100% ±
10% in wild-type mice; t statistic = 2.54, P = 0.03). No signif-
icant differences in expression of JAK-1 or JAK-2 were
observed in cerebral cortex (data not shown).
Discussion
In this study, we demonstrate that COX-1-/- or COX-2-/- mice
exhibit significant changes in the hippocampus and cerebral
cortex transcriptome. Some differentially expressed genes
occur in both genotypes but most changes observed (>93%)
are unique to one isoform deletion and not the other. This
observation implies that despite the functional similarities of
Table 2
Expression of GABA and JAK signaling-related genes in brain of COX knockout mice
Gene name Region COX-1-/- COX-2-/-
GAT3 Cerebral cortex -42% (-1.86) +66% (+1.68)
GABRB1 Cerebral cortex - -28% (ND)
GABRB1 Hippocampus - -46% (-2.32)
JAK 1 Hippocampus +96% (+1.56) -
JAK 2 Hippocampus - -18% (-2.09)
Percentage change in expression, as validated by Q-PCR, is provided, along with microarray-determined z ratios (in parenthesis) for each genotype 
comparison. Janus kinase (JAK)1 and 2 expression are altered only in hippocampus of COX-1-/- and COX-2-/- mice. COX, cyclooxygenase; GABA, γ-
aminobutyric acid; GABRB1, GABA-A receptor subunit β1; GAT, GABA transporter; ND, not differentially expressed in microarray analysis.R14.6 Genome Biology 2007,     Volume 8, Issue 1, Article R14       Toscano et al. http://genomebiology.com/2007/8/1/R14
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the two COX isoforms in the metabolism of AA to eicosanoids,
they impact the basal physiology of the brain in different
ways. Because the end products of COX-mediated AA metab-
olism, through the subsequent action of thromboxane and
prostaglandin synthases, are the bioactive mediators of COX
activity, this study suggests that COX-1 or COX-2 specific end
products differentially affect the mouse brain transcriptome.
Altered expression of mitochondrial function and β 
oxidation genes
The selective changes in transmembrane and mitochondrial
genes in COX-2-/- but not COX-1-/- may be related to the dif-
ferent subcellular localization of the two COX isoforms [11].
The deletion of COX-2, normally localized at nuclear enve-
lope [11], might affect the expression of genes directly or indi-
rectly coupled with COX-2. Although coupling between COX-
2 and mitochondrial enzymes in brain has not been reported,
mitochondrial localization of COX-2 has been reported in
cancer cells and in corpus luteum [12,13]. Our observation
that important genes involved in mitochondrial energy
metabolism are upregulated in the cerebral cortex of COX-2-/
-  mice suggests that COX-2 is critical for mitochondrial
function.
Our findings demonstrate that expressions of HADH2,
ACAT1, and ACLY mRNA were upregulated in the cerebral
cortex of COX-2-/- mice. The protein products of these genes
work in tandem to metabolize lipids, through the process of β
oxidation, to acetyl-coenzyme A [14-16].
The consequences of an increase in brain expression of three
major enzymes involved in the β oxidation of lipids implies an
increase in β oxidation of fatty acids in COX-2-/- mice. Sup-
porting this hypothesis, a previous study examining the
incorporation of AA in the brains of COX-2-/- mice [17] sug-
gested that the increase in baseline incorporation of AA in
awake COX-2-/- mice is possibly due to increased β oxidation.
Because a component of the kinetic model used by Rapoport
and coworkers allows for the possibility of a portion of the
infused AA to be shunted to β oxidation [18], it is possible that
the increased incorporation of AA in the brains of COX-2-/-
mice represents increased β oxidation mediated by an
increase in HADH2, ACAT1, and ACLY. However, it remains
unclear why the deletion of COX-2, but not COX-1, would
result in an increase in β oxidation enzymes in the brain.
Although these enzymes function in tandem in the β oxida-
tion pathway of lipid metabolism, HADH2 has been shown to
play a role in modifying the susceptibility of mouse brain to
certain insults. Transgenic mice overexpressing HADH2 have
proved to be more resistant to the brain damage associated
with MCAO and MPTP [8,9]. Similarly, COX-2-/- mice also
exhibit increased resistance to MPTP and MCAO induced
neuronal damage [8,9]. It is unclear whether increased
expression of HADH2 in COX-2-/- mice, as observed in the
present study, contributed to those previous findings, but it is
interesting that mice overexpressing HADH2 and COX-2-/-
mice are both resistant to the aforementioned nervous system
insults.
Altered expression of homocysteine metabolism genes 
in the cerebral cortex of COX-2-/- mice
Our study demonstrated that the expressions of MAT2B and
AHCY mRNA, the protein products of which are two tandem
enzymes involved in methionine metabolism, are upregulated
in the cerebral cortex of COX-2-/- but not of COX-1-/- mice.
MAT2B increases the level of product inhibition of the MAT
holoenzyme [19,20]. Because increased levels of S-adenosyl-
methionine are observed when MAT2B is downregulated
[19], we could predict that increased expression of MAT2B, as
observed in our study, would result in decreased S-adenosyl-
methionine, which is the exclusive methyl donor for trans-
methylation reactions [19-21].
Being the sole enzyme known to metabolize S-adenosylhomo-
cysteine, which is the product of transmethylation reactions,
AHCY regulates all S-adenosylmethionine dependent methyl-
transferases [22]. Increased expression of AHCY in the cortex
of COX-2-/- mice is predicted to increase the production of
adenosine and homocysteine [23]. The suggestion that an
increase in homocysteine production may occur in COX-2-/-
mice is intriguing because homocysteine is known to activate
endogenous glutamate receptors and potentiate the effect of
certain excitotoxins such as kainic acid [24,25]. The possibil-
ity that increased expression of AHCY results in elevated
homocysteine concentrations is consistent with a preliminary
observation made in our laboratory indicating that COX-2-/-
mice, but not COX-1-/- mice, have increased seizure intensity
and neuronal damage after systemic injection with kainic acid
[26]. Our findings support the observation that homocysteine
pretreatment increases the intensity of kainate-induced sei-
zures and neuronal damage [25].
Altered expression of GABA neurotransmission genes 
in COX-1-/- and COX-2-/- mice
We have identified two differentially expressed genes,
GABRB1 and GAT3, from the cortical and hippocampal
GABAergic system of COX deficient mice. GABRB1 is a β sub-
unit of the GABAA  ionotropic receptor ion channel [27].
GABRB1 mRNA is known to be downregulated by persistent
GABAA receptor activation and in a model of temporal lobe
epilepsy [28,29]. It is well established that a decrease in
GABA receptor number is preceded by a decrease in GABA
receptor subunit mRNA [30]. Therefore, our finding that
GABRB1 mRNA expression is decreased suggests a downreg-
ulation of GABA ionotropic receptor in the hippocampus and
cerebral cortex of COX-2-/- mice but not COX-1-/- mice.
Coupled with changes in GABRB1 in COX-2-/- mice, we also
demonstrated an alteration in the expression of a GABA
transporter. This transporter, GAT3, is thought to terminatehttp://genomebiology.com/2007/8/1/R14 Genome Biology 2007,     Volume 8, Issue 1, Article R14       Toscano et al. R14.7
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the GABA signal by transporting GABA from the synapse into
the cell [31-33]. The alteration in GAT3 expression observed
in the present study suggests an increased level of inhibitory
input in COX-1-/- mice, whereas COX-2-/- mice may have less
inhibitory input because of altered rates of GABA uptake from
the synapse. In fact, increased expression of GAT3 has been
demonstrated to be associated with epileptogenic hippocam-
pal tissue [34]. Furthermore, it has been shown that overex-
pression of GAT in transgenic mice increases their
susceptibility to kainate-induced seizures [35].
The combined effect of decreased expression in GABRB1 and
an increase in GAT3 in COX-2-/- mice, but not COX-1-/- mice,
is also consistent with preliminary data from our group dem-
onstrating an increased susceptibility of COX-2-/- mice, but
not COX-1-/- mice, to kainate induced excitotoxicity [26]. The
net effect of the alterations in GABA-related gene expression
in the COX-2-/-  mouse brain would suggest decreased
GABAergic tone, predisposing these mice to an increased
neuronal excitability that would increase their susceptibility
to excitotoxins such as kainate. Although our observations in
the present study are consistent with our previous data [26],
it remains to be determined how deletion of COX-2, but not of
COX-1, alters the expression of GABAergic system related
genes.
COX genotype-dependent alteration of Janus kinase 
isoforms in the mouse hippocampus
JAK1 and JAK2 are non-receptor tyrosine kinases that are
essential for the signal transduction of cytokine receptor acti-
vation (For reviews, see Aringer and coworkers [36] and
Leonard and O'Shea [37]). Both isoforms are ubiquitously
expressed but are involved in the transduction of specific
groups of cytokine signals [36,37]. Furthermore, JAK1 and
JAK2 knockout mice demonstrate the importance and nonre-
dundancy of these JAK isoforms, because both mutations are
lethal [36].
We found that JAK1 mRNA expression, but not that of JAK2,
is increased in the hippocampus of COX-1-/- mice, and that
JAK2, but not JAK1, is decreased in the hippocampus of COX-
2-/- mice. Although this is the first report to demonstrate a
JAK alteration in COX-/- mice, COX-2 inhibitors have been
shown to dampen interleukin-12 signaling by inhibiting the
activation of JAK2 [38]. Although it is unclear how these
alterations affect the brain physiology of the knockout mice,
one could predict a different response of COX-1-/- and COX-2-
/- mice to neuroinflammation caused by the role played by
JAK in regulating inflammation-induced signaling. Interest-
ingly, the pattern of change in JAK expression is similar to
what has been observed for NF-κB in the brains of COX-1-/-
and COX-2-/- mice [6,7]. COX-1-/- mice exhibit an upregula-
tion of the activity and expression of NF-κB accompanied by
an increase in I-κB phosphorylation [6]. Conversely, COX-2-/
- mice exhibit decreased expression and activation of NF-κB
accompanied by a decrease in I-κB phosphorylation [7].
Although the mechanism of crosstalk between the JAKs and
NF-κB has not been elucidated, evidence suggests that JAK
may be required for NF-κB activation [39]. In this regard, the
similarity in direction of expression of JAK and NF-κB based
on COX isoform deficiency is intriguing and requires further
study.
Conclusion
The present study is the first to demonstrate the specific effect
of genetic ablation of COX-1 or COX-2 on the mouse brain
transcriptome. Our findings suggest that ablation of COX
activity alters the transcription of many genes, including
those involved in β oxidation, methionine metabolism, GABA
neurotransmission, and cytokine signaling. Although some of
the molecular mechanisms underlying these changes are not
well understood at this time, these data identify metabolic
and signaling pathways that were previously not known to be
affected by COX. Because many anti-inflammatory and anal-
gesic treatments, such as nonsteroidal anti-inflammatory
drugs, rely on reduction in COX activity for their mechanism
of action, the specific alterations observed in this study
expand our understanding of the therapeutic and toxicologic
consequences of COX inhibition.
Materials and methods
Animal procedure
COX-1-/-  or COX-2-/-  mice and respective wild-type mice
(C57BL6/6-129/Ola mixed genetic background) [4] were
received at the animal facility of the National Institute on
Aging at 6 weeks of age from the National Institute of Envi-
ronmental Health Sciences colony maintained by Taconic
Farms (Germantown, NY, USA), with heterozygous by heter-
ozygous breedings for more than 35 generations. The
heterozygotes are maintained independently for each COX
line. F1 offspring of these heterozygous × heterozygous mat-
ings are then mated wild-type × wild-type to generate the
wild-type mice used in the study. Male homozygous null mice
(-/-) are mated with heterozygous female mice (+/-) to gener-
ate the -/- mice used in the present study. Thus, all mice used
in the study were one generation from the heterozygous ×
heterozygous maintenance colony. COX-1-/-  and COX-2-/-
mice were then compared with respective wild-type mice
(COX-1+/+ and COX-2+/+, respectively) for microarray and Q-
PCR analysis.
Mice were housed at room temperature on a 12 hour light/
dark cycle with free access to food and water in a ventilated
cage rack system. At 12 weeks of age the mice were killed with
an overdose of sodium pentobarbital (100 mg/kg) followed by
decapitation. Brains were quickly removed, dissected, and
stored at -80°C until usage. All procedures involving mice
were approved by the National Institutes of Child Health and
Human Development Animal Care and Use Committee, and
were performed in accordance with National Institutes ofR14.8 Genome Biology 2007,     Volume 8, Issue 1, Article R14       Toscano et al. http://genomebiology.com/2007/8/1/R14
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Health guidelines on the care and usage of laboratory
animals.
RNA extraction and cDNA synthesis
Fresh frozen mouse hippocampus and cerebral cortex were
processed for RNA extraction using the Qiagen RNeasy Lipid
Tissue Mini kit (Qiagen, Valencia, CA, USA) under RNAse-
free conditions by following the manufacturer's suggested
procedure. RNA purity and integrity were verified by examin-
ing the 260 nm/280 nm ratio using a spectrophotometer and
an ethidium bromide-agarose gel imaged under UV light,
respectively. Extracted RNA was resuspended in RNAse-free
molecular grade water and stored at -80°C until use. For Q-
PCR, total RNA (5 μg) was reverse transcribed using a High
Capacity cDNA Archive kit (Applied Biosystems, Foster City,
CA, USA) using appropriate controls to ensure the absence of
genomic DNA contamination.
Microarray procedures
Microarray procedure protocols used in the study are
described in the National Institute on Aging Gene Expression
and Genomic Unit website [40]. Briefly, 5 μg total RNA was
reverse transcribed in the presence of 33P-dCTP, and labeled
cDNA was purified using a Biospin P-30 column (Bio-Rad,
Hercules, CA, USA). A custom 17 K mouse nylon membrane
microarray (GEO: GPL4006) was used for the high through-
put analysis, which was performed in triplicate for each sam-
ple. Labeled cDNA from cerebral cortex and hippocampus of
COX-1-/-, COX-2-/-, COX-1+/+, and COX-2+/+ (three mice per
group) was hybridized to the nylon array for 16 to 18 hours.
Arrays were washed, dried, and apposed to a phosphoimager
screen for collection of data. Differentially expressed genes
were identified by comparing the microarray data from COX-
1+/+ with those from COX-1-/- mice and, separately, by com-
paring the data from COX-2+/+ with those from COX-2-/- mice
(as described below). Microarray images were processed
using ArrayPro (MediaCybernetics, Silver Spring, MD, USA);
the raw data were transferred to an Excel spreadsheet and
normalized using an Excel macro to convert raw data to Z
normalization, as previously described, with the following
equation [41]:
Z (raw data) = (ln [raw data] - avg [ln(raw data)])/(std dev
[ln(raw data)])
Where avg is the average of all genes of an array, and std dev
is the standard deviation of all genes of an array. This conver-
sion compresses the dataset onto a log scale, normalizes the
data to be symmetric around zero, and results in a standard
deviation of 1, allowing data to be compared between arrays.
Differentially expressed genes were identified using DIANE
1.0, a JMP (SAS Institute, Inc., Cary, CA, USA) based program
developed by VVP. (Information on availability and compo-
nents of DIANE can be found on the web [42]). DIANE 1.0
takes three factors into account to identify differentially
expressed genes. First, for a gene to be considered differen-
tially expressed, it must have similar values (both direction of
change and magnitude) between replicate arrays, as assessed
by the Z test, which results in a P value that is calculated using
a normal distribution [41]. Second, the fold change between
treatments is determined by z ratio:
z ratio (between treatment A and B) = (z [a] - z [b])/std dev
Where std dev is the standard deviation of all genes on an
array. Because the z normalized data have a standard devia-
tion of exactly 1, a significant fold change was considered to be
represented by any change greater than 1.5 times the stand-
ard deviation, that is, a z ratio greater than 1.5. This threshold
has been stated to result in consistent detection of differen-
tially expressed genes [41]. To avoid detection of background
level genes that may produce high fold changes and therefore
contribute to false detection rates, we eliminate all genes
below background by ensuring that the average intensity of a
gene over replicates of treatment and control exceeds zero.
This is enabled by the fact that the mean of z normalized
arrays is always zero. Once processed as above, the data can
be divided into five different significance levels: significance
level +2 = z ratio >1.5 and significant replication (P < 0.05);
significance level +1 = z ratio >1.5 and no significant replica-
tion (P > 0.05); significance level 0 = neither condition is
true; significance level -1 = same as +1 but wild type > knock-
out; and, finally, significance level -2 = same as +2 but wild
type > knockout
Genes that attain significance levels of +2 and -2 are highly
significant and are considered differentially expressed
between experimental groups. These genes are imported to
Excel from DIANE according to name, symbol, gene acces-
sion number, function, significance level, and z score. Further
annotation and analysis of the microarray dataset was
performed using DRAGON [43] and Ingenuity Pathways
(Ingenuity Systems, Redwood City, CA, USA). We did not
explicitly calculate false-positive or false-negative rates for
our microarray analysis because we used the z normalization
primarily as a filter for selecting candidate genes for Q-PCR
validation, which was carried out as described below.
Quantitative PCR analysis
A total of nine genes detected by microarray analysis were
validated using Q-PCR. These genes were selected because
they were differentially expressed in the microarray analysis.
In addition, these genes were selected for further validation
because they comprised distinct biologic functions or signal-
ing pathways, as determined by analysis using the Ingenuity
Pathways software.
Validation of microarray results (n = 5-6/group) was per-
formed using Q-PCR, with the ABI PRISM 7000 Sequence
Detection System (Applied Biosystems). To increase the sam-
ple size and further validate our microarray results, to the
same set of RNA samples used for microarray analysis (n = 3),http://genomebiology.com/2007/8/1/R14 Genome Biology 2007,     Volume 8, Issue 1, Article R14       Toscano et al. R14.9
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a new set of RNA samples obtained from independent ani-
mals (n = 3) was added for each experimental group for Q-
PCR analysis. In order to validate both positive and negative
findings of the microarray analysis completely, all possible
comparisons for genotype were performed in each brain
region for each gene described below. All changes detected by
microarray analysis were validated by Q-PCR. However, only
changes in gene expression detected by Q-PCR that were sta-
tistically significant are described in the results section,
whereas Q-PCR analyses that did not detect significant differ-
ential gene expression are provided in Additional data files.
Assay-on-Demand (Applied Biosystems) primers for ACAT1
(Unigene ID-Mm.293233), MAT2B (Unigene ID-
Mm.293771), AHCY (Unigene ID-Mm.330692), HADH2
(Unigene ID-Mm.6994), GAT3 (Unigene ID-Mm.258596;
also known as solute carrier family 6, member 13), GABRB1
(Unigene ID-Mm.226704), JAK1 (Unigene ID-Mm.289657),
JAK2 (Unigene ID-Mm.275839), and ACLY (Unigene ID-
Mm.282039) were used for Q-PCR validation of microarray
results. Q-PCR results for the above listed genes were normal-
ized to phosphoglycerate kinase 1 expression levels, as previ-
ously reported [5,6]. Briefly, Taqman Universal PCR Master
Mix, Assay-On-Demand primers, and cDNA samples were
mixed in RNAse-free water and added to an optical 96-well
reaction plate (Applied Biosystems). Negative controls con-
taining no cDNA and a standard curve spanning three orders
of magnitude of dilution were run on each plate in duplicate.
Q-PCR conditions were 50°C for 2 min and 95°C for 10 min,
followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. The
amou n t of  ta rg e t g en e  ex pr es sion  wa s ca lcu la te d by u sin g
either the ΔΔCT method [44] or by using the standard curve to
determine the absolute quantity of transcript. Following the
method of previous reports [5,6], relative expression values of
genes are expressed as percentage of expression in wild-type
mice.
Statistical analysis
Data are expressed as z ratio of microarray data or mean per-
centage difference ± standard deviation from gene expression
values in wild-type mice. Statistical analysis for Q-PCR data
was performed using the freeware program Open Stat 4 [45].
For all comparisons, the F test for homogeneity of variance
was first calculated. Depending on the results of the F test, an
unpaired t-test assuming equal variance or an unpaired t-test
assuming unequal variance was calculated. The t statistic and
P value for each comparison is reported. P < 0.05 was consid-
ered statistically significant.
Additional data files
The following additional data are available with the online
version of this article. Additional data file 1 provides a full list
of differentially expressed genes in cerebral cortex. Addi-
tional data file 2 provides a full list of differentially expressed
genes in hippocampus. Additional data file 3 provides raw
data for all Q-PCR analyses.
Additional data file 1 A full list of differentially expressed genes in cerebral cortex A full list of differentially expressed genes in cerebral cortex. Click here for file Additional data file 2 A full list of differentially expressed genes in hippocampus A full list of differentially expressed genes in hippocampus. Click here for file Additional data file 3 Raw data for all Q-PCR analyses Raw data for all Q-PCR analyses. Click here for file
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